Asthma affects 8% of the US population, approximately 25 million people. About 10% of patients have severe asthma, accounting for an estimated 1.8 million emergency department visits, 439,000 hospitalizations, and 3,630 deaths annually in the US .
Airway inflammation in asthma can be classified as either eosinophilic or non-eosinophilic. Eosinophilic asthma is driven by Th2 mechanisms sustained by innate lymphoid cells type 2 (ILC2) and pathogenic effector Th2 (pETh2) cells’ production of interleukin 5 (IL-5), leading to bronchial eosinophilia. Non-eosinophilic asthma is less well understood but Th17 pathways are a major contributor, responsible for neutrophilic infiltration of the airways .
The proposed technology is designed to treat both eosinophilic and non-eosinophilic asthma via a therapeutic monoclonal antibody (mAb) designed to work via targeting depletion of innate lymphoid cells type 2 (ILC2), pathogenic effector Th2 (pETh2) cells, and Th17 cells.